Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.47 |
| ▸ | TEK | Q02763 | 3/20 | 0.47 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 9/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15501031 | 0.94 | KDR (0.48) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4324526 | 0.89 | KDR (0.48) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4332993 | 0.88 | KDR (0.48) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4318354 | 0.87 | RAF1 (0.55) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4336983 | 0.85 | KDR (0.46) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4321789 | 0.83 | CYP1A2 (0.49) | KDRTEKEPHB4RAF1KDM4E | |
| SCHEMBL4325571 | 0.80 | RAF1 (0.47) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4325563 | 0.80 | RAF1 (0.45) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4321699 | 0.79 | KDR (0.51) | KDRTEKEPHB4RAF1BRAF | |
| SCHEMBL4323326 | 0.78 | RAF1 (0.57) | KDRTEKEPHB4RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | claimed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | claimed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | claimed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| EP-1858877-B1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | GILEAD CONNECTICUT INC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625931-B2 | 1-(5-Chloro-2,4-dimethoxy-phenyl)-3-[3-(2-pyridin-4-yl-imidazol-1-ylmethyl)-phenyl]-urea; treating cancer and diseases characterized by a change in angiogenesis; breast neoplasia, endometrial cancer, colon and neck cancer | CGI PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1858877-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI Pharmaceuticals, Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076592-A1 | 1,3 SUBSTITUTED DIARYL UREAS AS MODULATORS OF KINASE ACTIVITY | CGI PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211738-A1 | Certain substituted diphenyl ureas, as modulators of kinase activity | UCK2, AXL, CHUK | KDR 55/4885TEK 245/4885EPHB4 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.